of such data should, for a period of 12 years, be able to claim compensation from those
registrants who benefit from that data.
(53) in order to allow a potential registrant of a phase-in substance to proceed with his
registration, even if he cannot reach agreement with a previous registrant, the agency, on
request, should allow use of any summary or robust study summary of tests already
submitted. the registrant who receives these data should be obliged to pay a contribution
to the costs to the owner of the data. for non-phase-in substances, the agency may ask for
evidence that a potential registrant has paid the owner of a study before the agency gives
permission for the potential registrant to use that information in his registration.